A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.

被引：0
|
作者：
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Mazumder, Amitabha
Chamoun, Kamal
Karasik, Igor
Sbar, Eric
Dugon, Laura
Tamir, Sharon
Wang, Xulong
Prchal, Josef T.
Tantravahi, Srinivas Kiran
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Mt Sinai St Lukes Roosevelt Hosp, New York, NY USA
[3] VCU Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ Sch Med, Nashville, TN USA
[5] Oncol Inst Hope Innovat, Tampa, FL USA
[6] Karyopharm Therapeutics Inc, Newton, MA USA
[7] Karyopharm Therapeut, Newton, MA USA
[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[9] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7060
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [2] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    [J]. BLOOD, 2022, 140 : 3986 - 3987
  • [3] A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
    Heidel, Florian
    Ribrag, Vincent
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Kindler, Thomas
    Martino, Bruno
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Binlich, Florence
    Liu, Tracy
    Mu, Song
    Harrison, Claire N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.
    Mascarenhas, John
    Maher, Keri Renee
    Rampal, Raajit
    Bose, Prithviraj
    Podoltsev, Nikolai Alexandrovich
    Hong, Junshik
    Wang, Xulong
    Kye, Steve
    Harrison, Claire
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    Verstovsek, S.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O.
    Jamieson, C.
    Stein, B.
    Uno, T.
    Mesa, R. A.
    [J]. LEUKEMIA, 2017, 31 (02) : 393 - 402
  • [6] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    S Verstovsek
    M Talpaz
    E Ritchie
    M Wadleigh
    O Odenike
    C Jamieson
    B Stein
    T Uno
    R A Mesa
    [J]. Leukemia, 2017, 31 : 393 - 402
  • [7] Open-label dose-escalation study of oral 1-octanol in patients with essential tremor
    Shill, HA
    Bushara, KO
    Mari, Z
    Reich, M
    Hallett, M
    [J]. NEUROLOGY, 2004, 62 (12) : 2320 - 2322
  • [8] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
    Passamonti, Francesco
    Foran, James M.
    Tandra, Anand
    De Stefano, Valerio
    Fox, Maria Laura
    Mattour, Ahmad Hatem
    McMullin, Mary Frances
    Perkins, Andrew
    Rodriguez-Macias, Gabriela
    Sibai, Hassan
    Qin, Qin Q.
    Potluri, Jalaja
    How, Jonathan B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [10] Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
    Gore, Martin E.
    Jones, Robert J.
    Ravaud, Alain
    Kuczyk, Markus
    Demkow, Tomasz
    Bearz, Alessandra
    Shapiro, Joann
    Strauss, Uwe Phillip
    Porta, Camillo
    [J]. BJU INTERNATIONAL, 2017, 119 (06) : 846 - 853
12345